INO SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

NEWINOVIO Announces Proposed Public Offering of Common Stock

Nov 9, 2026

8-K

Inovio Pharmaceuticals Reports Preliminary Cash and Investments of $48.4 Million as of September 30, 2026

Nov 5, 2026

8-K

INOVIO Announces FDA Accelerated Approval of VOCERYQ™ for Recurrent Respiratory Papillomatosis (RRP)

Nov 2, 2026

8-K

Inovio Pharmaceuticals Adopts Bylaws Amendment Establishing Exclusive Forum Provisions

Oct 6, 2026

8-K

INOVIO Reports Second Quarter 2026 Financial Results and Provides Update on INO-3107 Regulatory Progress

Aug 12, 2026

8-K

INOVIO Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

Jul 31, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

FWP

OFFERING

Nov 5, 2026

S-3

July 2026 SHELF

Jul 2, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 22, 2026

S-3/A

SHELF EFFECTIVE

Jan 26, 2024

S-3

SHELF | Offering amount: $300,000,000.00 EFFECTIVE

Nov 9, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 18, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 11, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Nov 28, 2023

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Nov 17, 2023

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 31, 2023

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G/A

Adage Capital Management, L.P. (Filed by)

Aug 12, 2026

SCHEDULE 13G

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 7, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Aug 6, 2026

SCHEDULE 13G

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Jul 31, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jul 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 13, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 1, 2024

CORRESP

Form CORRESP - Correspondence

Jan 29, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 16, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 4, 2023

LETTER

Form UPLOAD - SEC-generated letter

Oct 14, 2022

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

NEWINOVIO Announces Proposed Public Offering of Common Stock

Nov 9, 2026

8-K

Inovio Pharmaceuticals Reports Preliminary Cash and Investments of $48.4 Million as of September 30, 2026

Nov 5, 2026

8-K

INOVIO Announces FDA Accelerated Approval of VOCERYQ™ for Recurrent Respiratory Papillomatosis (RRP)

Nov 2, 2026

8-K

Inovio Pharmaceuticals Adopts Bylaws Amendment Establishing Exclusive Forum Provisions

Oct 6, 2026

8-K

INOVIO Reports Second Quarter 2026 Financial Results and Provides Update on INO-3107 Regulatory Progress

Aug 12, 2026

8-K

INOVIO Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

Jul 31, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

FWP

OFFERING

Nov 5, 2026

S-3

July 2026 SHELF

Jul 2, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 22, 2026

S-3/A

SHELF EFFECTIVE

Jan 26, 2024

S-3

SHELF | Offering amount: $300,000,000.00 EFFECTIVE

Nov 9, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 18, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 11, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Nov 28, 2023

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Nov 17, 2023

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 31, 2023

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G/A

Adage Capital Management, L.P. (Filed by)

Aug 12, 2026

SCHEDULE 13G

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 7, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Aug 6, 2026

SCHEDULE 13G

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Jul 31, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jul 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 13, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 1, 2024

CORRESP

Form CORRESP - Correspondence

Jan 29, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 16, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 4, 2023

LETTER

Form UPLOAD - SEC-generated letter

Oct 14, 2022

Inovio Pharmaceuticals, Inc. INO · SEC Filings